CD8A and cancer: By decreasing the levels of FoxP3 and Treg, increasing the cytotoxicity of NK and CD8+T cells, and increasing the production of proinflammatory cytokines, HDAC inhibitors are conducive to reducing tumor formation and boosting an efficient immune response against cancer cells (102, 103).